FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Eugia Recalls Methocarbamol Injection Lot

Eugia U.S. recalls one lot of methocarbamol injection due to a customer product complaint about the presence of white particles floating inside a vial...

latest-news-card-1
Human Drugs

FDA OKs Expanded Use for Hepatitis B Drug

FDA approves a Gilead Sciences supplemental NDA for Vemlidy (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B vi...

Medical Devices

Synaptive Medical Fluorescence Module Cleared

FDA clears a Synaptive Medical 510(k) for its near-infrared fluorescence visualization module, Modus IR, adding to the existing fluorescence offering ...

latest-news-card-1
Biologics

Medexus Hemophilia B Factor Gets Expanded Use

FDA approves a Medexus Pharmaceuticals supplemental BLA for Ixinity [coagulation factor IX (recombinant)] for treating pediatric patients under 12 yea...

latest-news-card-1
Federal Register

FDA Withdraws 30 No-Longer-Marketed ANDAs

Federal Register notice: FDA withdraws approval of 30 abbreviated new drug applications from multiple applicants because the drug products are no long...

latest-news-card-1
Federal Register

OTC Monograph Drug User Fees

Federal Register notice: FDA announces the over-the-counter Monograph Drug User Fee Program facility fee rates for fiscal year 2024.

latest-news-card-1
Human Drugs

2 REMS Assessment MAPPs

CDER publishes two MAPPs on elements of REMS assessments.

latest-news-card-1
Medical Devices

FDA Fails to Follow Science in Electroshock Case: Attorneys

Two attorneys who represented the Canton, MA-based Judge Rotenberg Center in its court case against FDAs efforts to ban the use of an electroshock or ...

latest-news-card-1
Biologics

BIO Suggestions for CGT Potency Guidance

The Biotechnology Innovation Organization suggests ways FDA can improve a draft guidance on potency assurance for cellular and gene therapy products.

latest-news-card-1
Human Drugs

Catalent Indiana FDA-483

FDA releases the form FDA-483 with six observations from an inspection at the Catalent Indiana drug manufacturing facility.